个性化医疗的经济评估：对真实世界数据的需求 - Suppr

Economic evaluation of personalized medicine: a call for real-world data.

作者信息

Terkola Robert, Antoñanzas Fernando, Postma Maarten

机构信息

University of Florida-College of Pharmacy, Gainesville, USA.

Unit of PharmacoTherapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

DOI:10.1007/s10198-017-0890-x

PMID:28382502

Abstract

摘要

相似文献

Economic evaluation of personalized medicine: a call for real-world data.

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

Conducting economic evaluation based on basket clinical trial in the area of precision medicine.

Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):169-171. doi: 10.1080/14737167.2021.1865158. Epub 2020 Dec 24.

Some economics on personalized and predictive medicine.

Eur J Health Econ. 2015 Dec;16(9):985-94. doi: 10.1007/s10198-014-0647-8. Epub 2014 Nov 8.

H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine.

Curr Pharm Biotechnol. 2016;17(10):926-9. doi: 10.2174/1389201017666160519112850.

Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction.

Value Health. 2017 Jan;20(1):30-31. doi: 10.1016/j.jval.2016.09.2405.

Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?

Int J Technol Assess Health Care. 2014 Apr;30(2):179-87. doi: 10.1017/S0266462314000142. Epub 2014 May 7.

Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.

Pharmacoeconomics. 2016 Jul;34(7):635-44. doi: 10.1007/s40273-016-0388-x.

Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.

Value Health. 2018 Jul;21(7):799-808. doi: 10.1016/j.jval.2017.12.022. Epub 2018 Feb 21.

The importance of test accuracy in economic evaluations of companion diagnostics.

J Comp Eff Res. 2015 Nov;4(6):569-77. doi: 10.2217/cer.15.41. Epub 2015 Nov 3.

Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.

J Clin Oncol. 2015 Dec 1;33(34):4112-7. doi: 10.1200/JCO.2015.61.2838. Epub 2015 Oct 12.

引用本文的文献

Regulated Pricing Decisions and Diagnostic Test Choices in Personalized Medicine: Navigating the Implications Within Legal Frameworks.

Risk Manag Healthc Policy. 2024 Nov 9;17:2763-2776. doi: 10.2147/RMHP.S475929. eCollection 2024.

How is Value Defined in Molecular Testing in Cancer? A Scoping Review.

Appl Health Econ Health Policy. 2025 May;23(3):409-424. doi: 10.1007/s40258-024-00901-4. Epub 2024 Jul 9.

Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.

BMC Cancer. 2024 Mar 7;24(1):316. doi: 10.1186/s12885-024-12038-7.

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.

Eur J Haematol. 2022 Jun;108(6):469-485. doi: 10.1111/ejh.13755. Epub 2022 Mar 2.

Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis.

Front Pharmacol. 2021 Oct 19;12:700012. doi: 10.3389/fphar.2021.700012. eCollection 2021.

The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group.

Curr Oncol. 2021 Sep 21;28(5):3649-3658. doi: 10.3390/curroncol28050311.

Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review.

Int J Environ Res Public Health. 2020 Feb 12;17(4):1171. doi: 10.3390/ijerph17041171.

Cost-effectiveness of precision medicine: a scoping review.

Int J Public Health. 2019 Dec;64(9):1261-1271. doi: 10.1007/s00038-019-01298-x. Epub 2019 Nov 15.

本文引用的文献

The Value of Medicines: A Crucial but Vague Concept.

Pharmacoeconomics. 2016 Dec;34(12):1227-1239. doi: 10.1007/s40273-016-0434-8.

Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.

EPMA J. 2015 Sep 30;6:19. doi: 10.1186/s13167-015-0041-3. eCollection 2015.

Is individualized medicine more cost-effective? A systematic review.

Pharmacoeconomics. 2014 May;32(5):443-55. doi: 10.1007/s40273-014-0143-0.

Current methodological issues in the economic assessment of personalized medicine.

Value Health. 2013 Sep-Oct;16(6 Suppl):S20-6. doi: 10.1016/j.jval.2013.06.008.

Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.

Value Health. 2013 Sep-Oct;16(6 Suppl):S1-3. doi: 10.1016/j.jval.2013.06.004.

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

Value Health. 2012 Dec;15(8):1162-71. doi: 10.1016/j.jval.2012.05.006. Epub 2012 Sep 7.

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.

Economic opportunities and challenges for pharmacogenomics.

Annu Rev Pharmacol Toxicol. 2010;50:423-37. doi: 10.1146/annurev.pharmtox.010909.105805.

Pharmacogenomics, evidence, and the role of payers.

Public Health Genomics. 2009;12(3):149-57. doi: 10.1159/000189627. Epub 2009 Feb 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Economic evaluation of personalized medicine: a call for real-world data.

作者信息

Terkola Robert, Antoñanzas Fernando, Postma Maarten

机构信息

University of Florida-College of Pharmacy, Gainesville, USA.

Unit of PharmacoTherapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

DOI:10.1007/s10198-017-0890-x

PMID:28382502

Abstract

摘要

相似文献

Economic evaluation of personalized medicine: a call for real-world data.

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

Conducting economic evaluation based on basket clinical trial in the area of precision medicine.

Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):169-171. doi: 10.1080/14737167.2021.1865158. Epub 2020 Dec 24.

Some economics on personalized and predictive medicine.

Eur J Health Econ. 2015 Dec;16(9):985-94. doi: 10.1007/s10198-014-0647-8. Epub 2014 Nov 8.

H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine.

Curr Pharm Biotechnol. 2016;17(10):926-9. doi: 10.2174/1389201017666160519112850.

Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction.

Value Health. 2017 Jan;20(1):30-31. doi: 10.1016/j.jval.2016.09.2405.

Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?

Int J Technol Assess Health Care. 2014 Apr;30(2):179-87. doi: 10.1017/S0266462314000142. Epub 2014 May 7.

Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.

Pharmacoeconomics. 2016 Jul;34(7):635-44. doi: 10.1007/s40273-016-0388-x.

Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.

Value Health. 2018 Jul;21(7):799-808. doi: 10.1016/j.jval.2017.12.022. Epub 2018 Feb 21.

The importance of test accuracy in economic evaluations of companion diagnostics.

J Comp Eff Res. 2015 Nov;4(6):569-77. doi: 10.2217/cer.15.41. Epub 2015 Nov 3.

Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.

J Clin Oncol. 2015 Dec 1;33(34):4112-7. doi: 10.1200/JCO.2015.61.2838. Epub 2015 Oct 12.

引用本文的文献

Regulated Pricing Decisions and Diagnostic Test Choices in Personalized Medicine: Navigating the Implications Within Legal Frameworks.

Risk Manag Healthc Policy. 2024 Nov 9;17:2763-2776. doi: 10.2147/RMHP.S475929. eCollection 2024.

How is Value Defined in Molecular Testing in Cancer? A Scoping Review.

Appl Health Econ Health Policy. 2025 May;23(3):409-424. doi: 10.1007/s40258-024-00901-4. Epub 2024 Jul 9.

Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.

BMC Cancer. 2024 Mar 7;24(1):316. doi: 10.1186/s12885-024-12038-7.

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.

Eur J Haematol. 2022 Jun;108(6):469-485. doi: 10.1111/ejh.13755. Epub 2022 Mar 2.

Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis.

Front Pharmacol. 2021 Oct 19;12:700012. doi: 10.3389/fphar.2021.700012. eCollection 2021.

The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group.

Curr Oncol. 2021 Sep 21;28(5):3649-3658. doi: 10.3390/curroncol28050311.

Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review.

Int J Environ Res Public Health. 2020 Feb 12;17(4):1171. doi: 10.3390/ijerph17041171.

Cost-effectiveness of precision medicine: a scoping review.

Int J Public Health. 2019 Dec;64(9):1261-1271. doi: 10.1007/s00038-019-01298-x. Epub 2019 Nov 15.

本文引用的文献

The Value of Medicines: A Crucial but Vague Concept.

Pharmacoeconomics. 2016 Dec;34(12):1227-1239. doi: 10.1007/s40273-016-0434-8.

Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.

EPMA J. 2015 Sep 30;6:19. doi: 10.1186/s13167-015-0041-3. eCollection 2015.

Is individualized medicine more cost-effective? A systematic review.

Pharmacoeconomics. 2014 May;32(5):443-55. doi: 10.1007/s40273-014-0143-0.

Current methodological issues in the economic assessment of personalized medicine.

Value Health. 2013 Sep-Oct;16(6 Suppl):S20-6. doi: 10.1016/j.jval.2013.06.008.

Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.

Value Health. 2013 Sep-Oct;16(6 Suppl):S1-3. doi: 10.1016/j.jval.2013.06.004.

Value Health. 2012 Dec;15(8):1162-71. doi: 10.1016/j.jval.2012.05.006. Epub 2012 Sep 7.

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.

Economic opportunities and challenges for pharmacogenomics.

Annu Rev Pharmacol Toxicol. 2010;50:423-37. doi: 10.1146/annurev.pharmtox.010909.105805.

Pharmacogenomics, evidence, and the role of payers.

Public Health Genomics. 2009;12(3):149-57. doi: 10.1159/000189627. Epub 2009 Feb 10.

Economic evaluation of personalized medicine: a call for real-world data.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Economic evaluation of personalized medicine: a call for real-world data.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献